Health · Medical Research · 6 hrs ago
NIH awards $7.6 million to expand rare disease research in Michigan
The NIH awarded a $7.6 million grant to expand rare disease research and care in Michigan.
The work involves Corewell Health and Michigan State University, along with partners including Johns Hopkins University and the Snyder-Robinson Foundation.
A Michigan child’s diagnosis helped identify Bachmann-Bupp Syndrome, a rare condition linked to a mutation in the ODC1 gene.
Researchers and clinicians then used DFMO, an existing medicine, to treat the child, Marley Berthoud, beginning in 2019.
Marley gained strength and her hair grew back within months, and she later made further developmental progress.
The grant supports a partnership between laboratory researchers and clinicians that helped turn research into treatment for a patient.
The team plans to extend this work to children with Bachmann-Bupp Syndrome, Snyder-Robinson Syndrome and related disorders.
The National Institutes of Health awarded a $7.6 million grant to expand rare disease research and clinical care in Michigan.
The grant was awarded jointly to Corewell Health and Michigan State University’s College of Human Medicine.
The work builds on the case of Marley Berthoud, whose diagnosis led to the identification of Bachmann-Bupp Syndrome and a treatment.
Marley was the first person treated with difluoromethylornithine, or DFMO, for the condition.
The grant’s partners also include Johns Hopkins University and the Snyder-Robinson Foundation.
- Who
- The National Institutes of Health awarded the grant to Corewell Health and Michigan State University’s College of Human Medicine.
- What
- A $7.6 million grant will expand rare disease research and clinical care.
- When
- The grant was reported on November 16, 2026.
- Where
- Michigan. The grant recipients are Corewell Health and Michigan State University’s College of Human Medicine.
- Why
- To expand research and care for Bachmann-Bupp Syndrome, Snyder-Robinson Syndrome and related polyamine disorders.
This story does not have two clearly opposing sides.
Marley Berthoud was born with symptoms including low muscle tone, developmental delays and complete hair loss.
Genetic testing and molecular research identified a mutation in Marley’s ODC1 gene, establishing the first recognized diagnosis of Bachmann-Bupp Syndrome.
Marley became the first person treated with DFMO for the condition.
Marley’s hair, eyelashes and eyebrows grew back, and she made physical and cognitive progress.
News-Medical reported that NIH had awarded the $7.6 million grant.
- Grant amount
- $7.6 million
- Lead recipients
- Corewell Health and Michigan State University College of Human Medicine
- Other partners
- Johns Hopkins University; Snyder-Robinson Foundation
- Patient
- Marley Berthoud, born in 2015
- Treatment
- Difluoromethylornithine (DFMO)
- First treatment
- Late 2019
What people are saying
It is so fulfilling when you see your laboratory research translate directly into helping a child at the clinic
This new grant lets us expand that hope to families everywhere with children who have Bachmann-Bupp Syndrome, Snyder-Robinson Syndrome or other related polyamine disorders
All of this work has been so rewarding because it started with a single patient